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Background: Yeast is recognized as a generally safe microorganism and is utilized for the production of
pharmaceutical products, including vaccines. We previously showed that expression of human immunodeficiency
virus type 1 (HIV-1) Gag protein in Saccharomyces cerevisiae spheroplasts released Gag virus-like particles (VLPs)
extracellularly, suggesting that the production system could be used in vaccine development. In this study, we
further establish HIV-1 genome packaging into Gag VLPs in a yeast cell system.
Results: The nearly full-length HIV-1 genome containing the entire 50 long terminal repeat, U3-R-U5, did not
transcribe gag mRNA in yeast. Co-expression of HIV-1 Tat, a transcription activator, did not support the transcription.
When the HIV-1 promoter U3 was replaced with the promoter for the yeast glyceraldehyde-3-phosphate
dehydrogenase gene, gag mRNA transcription was restored, but no Gag protein expression was observed.
Co-expression of HIV-1 Rev, a factor that facilitates nuclear export of gag mRNA, did not support the protein
synthesis. Progressive deletions of R-U5 and its downstream stem-loop-rich region (SL) to the gag start ATG codon
restored Gag protein expression, suggesting that a highly structured noncoding RNA generated from the R-U5-SL
region had an inhibitory effect on gag mRNA translation. When a plasmid containing the HIV-1 genome with the
R-U5-SL region was coexpressed with an expression plasmid for Gag protein, the HIV-1 genomic RNA was
transcribed and incorporated into Gag VLPs formed by Gag protein assembly, indicative of the trans-packaging of
HIV-1 genomic RNA into Gag VLPs in a yeast cell system. The concentration of HIV-1 genomic RNA in Gag VLPs
released from yeast was approximately 500-fold higher than that in yeast cytoplasm. The deletion of R-U5 to the
gag gene resulted in the failure of HIV-1 RNA packaging into Gag VLPs, indicating that the packaging signal of
HIV-1 genomic RNA present in the R-U5 to gag region functions similarly in yeast cells.
Conclusions: Our data indicate that selective trans-packaging of HIV-1 genomic RNA into Gag VLPs occurs in a
yeast cell system, analogous to a mammalian cell system, suggesting that yeast may provide an alternative
packaging system for lentiviral RNA.
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The yeast Saccharomyces cerevisiae has been used for many
years as a model organism with which to study biological
functions in higher eukaryotic cells. Such pioneering re-
search has employed yeast genetics (e.g., gene-deletion mu-
tant yeast) and molecular technologies (e.g., two-hybrid
assay) and has uncovered fundamental cellular functions* Correspondence: morikawa@lisci.kitasato-u.ac.jp
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reproduction in any medium, provided the orsuch as the cell cycle and mRNA turnover. Because of the
accumulated knowledge of cell biology and systematic
screening technologies, virologists have turned to the use of
yeast as a model cell system to study the host factors re-
quired for the replication of higher eukaryotic viruses [1].
For example, bromo mosaic virus, a positive-strand RNA
virus, has been shown to replicate and encapsidate its gen-
ome into virus particles in yeast [2], and the human papillo-
mavirus genome has been shown to replicate stably in yeasttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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quired for viral replication [4-6].
The applicability of yeast has been further expanded as
cells for vaccine development, since yeast is recognized as
generally safe and is utilized for the production of many
pharmaceutical products. A good example is the hepatitis B
surface antigen expressed in yeast, which is a safe and effi-
cient vaccine used worldwide [7]. Another is the human
papillomavirus capsid protein expressed in yeast, which is
currently available as a vaccine [8,9]. Both viral proteins are
self-assembled into virus-like particles (VLPs) in yeast ex-
pression systems, similar to mammalian and insect cell
systems. Such VLPs are noninfectious but highly immuno-
genic because they mimic authentic viral particle structures.
Consequently, VLPs represent new candidates for safe and
efficacious vaccine components.
Human immunodeficiency virus type 1 (HIV-1), a mem-
ber of the retrovirus family, is a causative agent for ac-
quired immunodeficiency syndrome. The HIV-1 genomic
RNA is reverse-transcribed into the cDNA and is inte-
grated into the host cell chromosome. This cDNA form
called proviral DNA is a template for transcription and
replication of the HIV-1 genome. The proviral DNA has
long terminal repeats (LTR) composed of unique region 30
end (U3), repeat (R), and unique region 50 end (U5) at both
ends. These ends are important for viral transcription and
replication: the U3 contains viral promoter and enhancer;
the R contains a Tat-responsive region (TAR) and a poly A
addition signal (pA); the U5 contains a primer binding site
(PBS) [10]. The U3-R junction is the transcription start site.
The 50 LTR is followed by stem-loop (SL) structure-
enriched untranslated region. SL1 and SL3 are a dime-
rization initiation signal (DIS) [11] and an encapsidation
signal Psi for the HIV-1 genome [12,13], respectively, and
both are absolutely required for HIV-1 genome packaging
into viral particles. The three major genes, gag, pol, and
env, encoding viral structural proteins, lie between the 50
and 30 LTRs. The gag gene encodes the viral capsid protein,
Gag, which is essential for retroviral particle assembly. The
pol and env genes encode viral specific enzymes and enve-
lope proteins, both of which are necessary for multiple
rounds of viral replication but are dispensable for viral par-
ticle production [14]. The HIV-1 genome also contains the
accessory genes, tat, rev, nef, vif, vpr, and vpu, all of which
contribute to efficient viral replication. The tat gene en-
codes Tat protein, which binds to the TAR sequence and is
obligatory for HIV-1 transcription, whereas the rev gene
encodes Rev protein, which binds to a highly structured
RNA region, termed the Rev-responsive element (RRE),
within the env gene and exports unspliced and incom-
pletely spliced HIV-1 RNAs to the cytoplasm [15]. Thus,
HIV-1 gene expression requires many RNA elements and
the viral regulatory proteins Tat and Rev, whereas HIV-1
particle production requires only Gag.Numerous protein expression systems, such as transfec-
tion with expression plasmids and infection with recombin-
ant viral vectors, have shown that Gag protein expression
alone in higher eukaryotic cells produces Gag VLPs, which
are morphologically identical to the immature form of
retroviral particles [16-19]. We previously showed that the
expression of HIV-1 Gag protein in S. cerevisiae and the
subsequent spheroplast formation produced Gag VLPs ex-
tracellularly [20]. We also showed that the Gag VLPs
encased in yeast cell membrane induced innate immune re-
sponses (e.g., cytokine production), suggesting that the
yeast production system has practical applications such as
vaccine development [21]. Since the RNA elements re-
quired for HIV-1 genome packaging are well defined and
distinct from the gag gene, it is possible that the addition of
these RNA elements produces the HIV-1 VLPs containing
the viral genome. In the present study, we tested this possi-
bility and established trans-packaging of the HIV-1 genome
into the Gag VLPs in a yeast cell system.
Results
Yeast did not support transcription or translation from
HIV-1 LTR
We initially analyzed the transcription of the HIV-1 LTR
promoter in S. cerevisiae. The 50 LTR of the HIV-1 cDNA
(with deletion of the env gene for biosafety) was left in-
tact, but the 30 LTR was replaced with the terminator
for the yeast glyceraldehyde-3-phosphate dehydrogenase
(GAP) gene (Figure 1A). This chimeric DNA was cloned
into yeast 2 μ plasmid pKT10 [22], and the yeast was
transformed with the recombinant plasmid (referred to
as HIV-TGAP). When RNA was purified from the trans-
formants and subjected to Northern blotting using a
minus-strand biotinylated RNA probe for the HIV-1 pol
gene, little or no HIV-1 RNA was detected (Figure 1B).
Co-transformation with a pRS plasmid containing the
HIV-1 tat gene with an expression cassette (the promoter
and terminator for yeast GAP) showed expression and
nuclear localization of the HIV-1 Tat protein (Figure 1D),
but the Tat protein did not transactivate the transcription
of HIV-1 genome from the LTR (Figure 1B). These ob-
servations were consistent with previous reports showing
that neither transcription from HIV-1 LTR nor transacti-
vation by Tat occurred in S. cerevisiae [23,24].
We further replaced the U3 of the 50 LTR (corresponding
to the HIV-1 promoter) by the promoter for yeast GAP (re-
ferred to as PGAP-HIV-TGAP). Northern blotting revealed
that this promoter rescued gag mRNA transcription
(Figure 1B). The full-length gag mRNA was accompanied
by some smaller RNA species, similar to the case with the
transcription of proviral HIV-1 molecular clone pNL43 [25]
observed in mammalian cells. Nonetheless, Gag protein ex-
pression was not observed when the whole cell lysates were
analyzed by Western blotting using anti-HIV-1 p24
Figure 1 (See legend on next page.)
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Figure 2 Inhibition of HIV-1 Gag protein expression by the R-U5 and SL regions in yeast. (A) Schematical representation of HIV-1
expression plasmids with deletions in the R-U5 and SL regions. (B) Semi-quantitative RT-PCR for HIV-1 RNA in yeast. Total cellular RNA was
isolated from yeast transformed with HIV-1 expression plasmids with deletions in the R-U5 and SL and was subjected to semi-quantitative RT-PCR
for HIV-1 gag mRNA and yeast actin mRNA. Using 300 ng of total cellular RNA, RT-PCR for HIV-1 gag mRNA and yeast actin mRNA was performed
up to 26 PCR cycles (upper). Using a series of dilutions of the cellular RNA (10 to 300 ng), RT-PCR for HIV-1 gag mRNA and yeast actin mRNA was
performed at 20 PCR cycles (lower). Representative blots were shown. The PCR product for HIV-1 gag mRNA corresponds to 670 bases and that
for yeast actin mRNA 840 bases. (C) Semi-quantification of HIV-1 RNA in yeast. Total cellular RNA of the yeast transformants was serially diluted
(3 to 1000 ng), slot-blotted, and detected by hybridization with the minus-strand RNA probe for the HIV-1 pol gene. Representative blots were
shown. (D) Real-time RT-PCR for HIV-1 RNA in yeast. Total cellular RNA isolated from yeast transformants was reverse-transcribed and aliquots of
the reaction samples were used for amplification up to 40 PCR cycles with specific primers for HIV-1 gag mRNA. Empty indicates total cellular
RNA isolated form yeast transformant with an empty pKT10 plasmid (negative control). Data were shown as means with standard deviations from
3 independent experiments. (E) HIV-1 Gag protein expression in yeast. Whole cell lysates of yeast transformed with HIV-1 expression plasmids
with deletions in the R-U5 and SL regions were subjected to Western blotting using and anti-HIV-1 p24 antibody. Representative blots
were shown.
(See figure on previous page.)
Figure 1 No transcription or translation from HIV-1 LTR in yeast. (A) Construction of yeast expression plasmids for HIV-1. In HIV-TGAP, the 3
0 LTR
of the HIV-1 cDNA (with deletion the env gene) was replaced with the terminator for the yeast GAP gene and was cloned into yeast 2μ plasmid pKT10.
In PGAP-HIV-TGAP, the 5
0 LTR U3 and 30 LTR of HIV-1 cDNA (with deletion the env gene) were replaced by the promoter and terminator for the yeast
GAP gene, respectively and were cloned into pKT10. (B) HIV-1 RNA synthesis in yeast transformed with HIV-1 expression plasmids. Yeast was
transformed with HIV-TGAP, HIV-TGAP plus HIV-1 Tat expression plasmids, PGAP-HIV-TGAP, or PGAP-HIV-TGAP plus HIV-1 Rev expression plasmids. Northern
blotting of the yeast transformants was performed using minus-strand biotinylated RNA probe for the HIV-1 pol gene. Representative blots were
shown. HeLa cells transfected with HIV-1 molecular clone pNL43 were used as control. A 0.24-9.5 kb RNA ladder (GIBCO BRL) were used as molecular
weight markers. (C) HIV-1 protein expression in yeast transformed HIV-1 expression plasmids. Yeast was transformed with HIV-1 expression plasmids as
described in (B) and whole cell lysate was subjected to Western blotting using anti-HIV-1 p24 antibody. Yeast transformed with HIV-1 Gag expression
plasmid was used as control. Representative blots were shown. Prestained 21–113 kDa protein markers (Bio-Rad) were used as molecular weight
markers. (D) Expression of HIV-1 Tat and Rev in yeast. Yeast transformed with HIV-1 Tat and Rev expression plasmids were subjected to spheroplast
formation and immunostaining using anti-HIV-1 Tat and Rev antibodies, respectively. Nuclei were stained with DAPI. Representative images were
shown at the same magnification.
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blocked at post-transcriptional steps in yeast (Figure 1C).
HIV-1 Rev binds to the RRE residing in HIV-1 RNA and fa-
cilitates the nuclear export of gag mRNA, unspliced mRNA
containing RRE, in mammalian cells. It has been reported
that Rev similarly functions dependently of RRE in yeast
[26,27]. However, the co-expression of Rev from a pRS
plasmid containing the rev gene with an expression cassette
(the promoter and terminator for yeast GAP) (Figure 1D)
did not support Gag protein expression (Figure 1C),
suggesting, although not proving, that HIV-1 gag mRNA
containing R-U5 was not efficiently translated in yeast.
The R-U5-SL region to the gag start ATG codon inhibited
Gag protein expression in yeast
HIV-1 gag mRNA is identical to its genomic RNA and
contains the R-U5-SL region at its 50 end. It is well docu-
mented that the R-U5-SL region forms a highly folded
and complicated structure [28-31]. To define the regions
that inhibited the translation of HIV-1 gag mRNA
in yeast, a series of 50 truncations was carried out in the
R-U5-SL region (Figure 2A), and the constructs were
similarly cloned into a pKT10 plasmid with a yeast ex-
pression cassette (the promoter and terminator for yeast
GAP) [22]. When the whole cell lysates were subjected to
Western blotting using anti-HIV-1 p24 antibody, the
construct containing the full length of the R-U5-SL (re-
ferred to as TAR-gag) showed no Gag protein expression.
In contrast, 50 truncations in the R-U5-SL (referred to as
PBS-gag and DIS-gag) partially restored Gag protein ex-
pression. The Gag protein level produced by the DIS-gag
was lower than that by the PBS-gag, in accordance with
previous reports on strong inhibition of gag mRNA
translation by the TAR [32-34] and SL regions [35].
Complete deletion of the R-U5-SL (referred to as gag)
fully restored Gag protein expression when compared
with yeast transformed with the Gag expression plasmid
containing the HIV-1 gag gene alone (Figure 2E).
Total cellular RNA was isolated from these yeast
transformants and was subjected to semi-quantitative
RT-PCR analysis for HIV-1 gag mRNA and yeast actin
mRNA. When the amplification kinetics were initially
monitored with 300 ng of cellular RNA, we found that
the RT-PCR products for both HIV-1 gag mRNA and
yeast actin mRNA increased as the number of PCR cycles
increased (up to 26 cycles) (Figure 2B, upper). Using a
series of dilutions of the cellular RNA, the product yields
at 20 PCR cycles indicated that all 50 truncation con-
structs produce largely similar levels of HIV-1 gag
mRNA (Figure 2B, lower). For the direct detection of
RNA, a series of dilutions of the cellular RNA was slot-
blotted on the membrane, followed by hybridization with
the RNA probe for the HIV-1 pol gene. The results con-
firmed that the 50 truncation constructs produced largelyequivalent levels of HIV-1 gag mRNA (Figure 2C). Real-
time RT-PCR analysis further confirmed these findings
(Figure 2D). These data indicate that the HIV-1 R-U5-SL
region that generates a highly structured RNA has an in-
hibitory effect on Gag translation in yeast, as reported in
mammalian cells [35,36].
Trans-packaging of HIV-1 genomic RNA into Gag VLPs in
a yeast cell system
In mammalian cells, HIV-1 gag mRNA is also used as viral
genomic RNA and is incorporated into viral particles. The
genomic RNA/gag mRNA has the encapsidation signal Psi
in the SL region, which is absolutely required for viral gen-
ome packaging into HIV-1 particles [37-39]. The SL re-
gion also includes a signal, termed dimerization initiation
site (DIS), which is essential for the dimerization of HIV-1
genomic RNA and overlaps with a signal required for the
packaging of the genomic RNA, suggesting that the di-
merization and packaging processes are possibly coupled
[40,41]. Several studies have indicated that other RNA ele-
ments (e.g., TAR and PBS) are also involved in the effi-
ciency of HIV-1 genome packaging [38,42,43]. From these
studies, we considered that the use of the same construct
for the synthesis of HIV-1 genomic RNA and Gag protein
(i.e., cis-packaging) was a less effective method for the
RNA packaging into Gag VLPs in the yeast cell system.
It is well known that the synthesis of retroviral genomic
RNA can be separated from that of Gag protein, and that
retroviral genomic RNA transcribed from a construct is
incorporated into Gag VLPs produced by another con-
struct in mammalian cells (i.e., trans-packaging) [44,45].
This method is extensively used for the production of viral
gene therapy vectors [46,47]. We investigated whether or
not trans-packaging is possible in a yeast cell system. To
this end, a plasmid containing the HIV-1 genome with the
R-U5-SL region (as a vector plasmid) was co-expressed
with the Gag expression plasmid containing the gag gene
alone (as a helper plasmid) in yeast. For comparison, a
plasmid containing the HIV-1 genome without the R-U5
-SL region or the gag start codon was similarly coex-
pressed with the Gag expression plasmid (Figure 3A). Fol-
lowing removal of the cell wall, yeast spheroplasts were
maintained under an isotonic condition overnight, and
Gag VLPs were purified from the culture medium by
ultracentrifugation, as described previously [20,48]. West-
ern blotting of the VLP fractions with anti-HIV-1 p24 anti-
body confirmed the production of Gag VLPs. When RNA
was isolated from equivalent volumes of the Gag VLP frac-
tions and was subjected to Northern blotting with the pol
RNA probe, we found the presence of HIV-1 genomic
RNA in the VLP fractions in coexpression with the HIV-1
genome with the R-U5-SL region. In contrast, no substan-
tial level of HIV-1 genomic RNA was observed in the
VLPs obtained in coexpression with the HIV-1 genome
Figure 3 Trans-packaging of HIV-1 genomic RNA into Gag VLPs in yeast. (A) Schematical representation of HIV-1 expression plasmids used
for trans-packaging. HIV-1 Gag expression plasmid was used for production of Gag VLPs (as a helper plasmid). PGAP-HIV-TGAP and PGAP-ΔHIV-TGAP
were used for synthesis of HIV-1 genomic RNA (as vector plasmids). (B) Production of HIV-1 Gag VLPs and packaging of HIV-1 RNA in yeast. Yeast
was cotransformed with the helper and vector plasmids. After removal of the cell wall, yeast spheroplasts were cultured overnight for Gag VLP
release. Cells and purified Gag VLPs were analyzed by Western blotting using anti-HIV-1 p24 antibody. RNA was isolated from cells and purified
Gag VLPs and was analyzed by Northern blotting using minus-strand biotinylated RNA probe for the HIV-1 pol gene. All blots are representative
from 3–4 independent experiments. (C) Electron microscopy of Gag VLPs. Purified Gag VLPs were analyzed by electron microscopy.
Representative micrographs were shown at the same magnification. Bar =100 nm.
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RNA in the cells was comparable (Figure 3B). It is known
that the retrovirus genomic RNA in viral particles is ran-
domly nicked and shows smear bands under denatured
conditions although it is intact in cells [49,50].
Electron microscopy confirmed no morphological differ-
ences in these Gag VLPs (Figure 3C). These data indicate
that trans-packaging of HIV-1 genomic RNA into Gag
VLPs is possible in a yeast cell system and is dependent on
the presence of the R-U5-SL region, similar to the case
with mammalian cell systems.
Selective packaging of HIV-1 genomic RNA into Gag VLPs
in a yeast cell system
We investigated to what extent HIV-1 genomic RNA was
selectively packaged into Gag VLPs. The total cellular
RNA and the VLP RNA were serially diluted and analyzed
by Northern blotting using the pol RNA probe (Figure 4A).
The RNA dilutions (from 10 to 0.1 μg in the case of total
cellular RNA; from 10 to 0.1 ng in the case of VLP RNA)
were also subjected to slot blotting and probed with the
RNA probe. When the endpoint dilutions were compared,
they were at 0.2 μg for the cellular RNA but at 1 ng for
the VLP RNA, indicating that the HIV-1 genomic RNA in
Gag VLPs was concentrated by approximately 500-fold
compared to the same RNA in yeast cells (Figure 4B). For
more accurate analysis, the unspliced HIV-1 RNA (con-
taining the SL region) present in the cellular RNA and
VLP RNA fractions was quantified by real-time RT-PCR.
The results revealed similarly approximately 500-fold con-
centration of HIV-1 genomic RNA in the VLP fraction(Figure 4D). In contrast, when the RNA dilutions were
slot-blotted and probed with the minus-strand RNA probe
for yeast actin mRNA, no preferential incorporation into
Gag VLPs was observed (Figure 4C). This is consistent
with a previous study, in which the majority of cellular
RNAs were nonselectively incorporated into retrovirus
particles [51]. Together, these data indicate selective pack-
aging of HIV-1 genomic RNA into Gag VLP in a yeast cell
system.
Transgene expression by Gag VLPs in mammalian cells
We finally tested whether the HIV-1 genomic RNA pack-
aged into yeast-produced Gag VLPs was expressed in
mammalian cells. The bicistronic reporter construct that
composed of the gag gene fused with a FLAG epitope tag
sequence, the IRES sequence derived from encephalomyo-
carditis virus, and the gene for enhanced green fluorescent
protein (egfp) was generated in a pNL43 derivative with
deletions of the pol gene and the env gene. In this con-
struct, GagFL is translated in a cap-dependent fashion,
whereas EGFP is in a cap-independent fashion under con-
trol of the IRES. The 30 LTR and the U3 of the 50 LTR
were replaced by the terminator and the promoter for the
yeast GAP gene, respectively, and the resultant construct
was cloned into yeast 2μ plasmid pKT10 [22] (referred to
as PGAP-GagFL-IRES-EGFP-TGAP). For trans-packaging of
this bicistronic reporter RNA into Gag VLPs, PGAP-
GagFL-IRES-EGFP-TGAP (as a vector plasmid) was co-
expressed with the Gag expression plasmid containing the
gag gene (as a helper plasmid) in yeast (Figure 5A). Yeast
spheroplast formation and Gag VLP production were
Figure 4 Preferential incorporation of HIV-1 genomic RNA into
Gag VLPs in yeast. (A) Efficiency of incorporation of HIV-1 genomic
RNA into Gag VLPs in yeast. Yeast was cotransformed with the Gag
expression plasmid (helper) and PGAP-HIV-TGAP plasmid (vector). After
spheroplast formation, cells were cultured overnight for Gag VLP
release from yeast spheroplasts were carried out as before. RNA was
isolated from yeast spheroplasts and Gag VLPs, serially diluted, and
analyzed by Northern blotting using minus-strand biotinylated RNA
probe for the HIV-1 pol gene. Representative blots were shown.
HeLa cells transfected with HIV-1 molecular clone pNL43 were used
as control. Arrow indicates gag mRNA. A 0.24-9.5 kb RNA ladder
(GIBCO BRL) were used as molecular weight markers. (B) Semi-
quantification of incorporation efficiency of HIV-1 genomic RNA into
Gag VLPs. RNAs of the yeast spheroplasts and Gag VLPs were serially
diluted, slot-blotted, and detected by with hybridization with the
minus-strand RNA probe for the HIV-1 pol gene. Representative blots
were shown. (C) Semi-quantification of incorporation efficiency of
yeast actin mRNA into Gag VLPs. RNAs of the yeast spheroplasts and
Gag VLPs were serially diluted, slot-blotted, and detected by with
hybridization with the minus-strand RNA probe for yeast actin
mRNA. Representative blots were shown. (D) Quantification of
incorporation efficiency of HIV-1 genomic RNA into Gag VLPs by
real-time RT-PCR. RNA was isolated from yeast spheroplasts or Gag
VLP and was reverse-transcribed. Aliquots of the reaction samples
were used for amplification up to 40 PCR cycles with specific
primers for unspliced HIV-1 mRNA. Data were shown as means with
standard deviations from 3 independent experiments.
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Gag VLPs for 2 days and were subjected to immunostain-
ing with anti-FLAG antibody. Neither GagFL nor EGFP
was detected by confocal microscopy (Figure 5B, upper).
We also used Raw264.7 cells (mouse monocytic macro-
phage-like cell line) because macrophage-like cells endo-
cytose exogenously added antigens more efficiently than
epithelial cells, but we failed to see expression of GagFL
and EGFP (data not shown). In contrast, transfection with
the pNL43 derivative cDNA containing the gag gene fused
with a FLAG sequence and the egfp gene exhibited expres-
sion of GagFL and EGFP (Figure 5B, lower).
Discussion
Transcription of HIV-1 genome in yeast
The 50 LTR of HIV-1 is composed of the U3-R-U5 and is
followed by the SL region. The U3 region is a promoter
and contains the binding sites for transcription factors, such
as nuclear factor κB, Sp1, and AP2. However, HIV-1 tran-
scription is regulated primarily by Tat protein. Tat binds to
the TAR sequence within the R region of HIV-1 mRNA
transcripts and recruits the host positive transcription
elongation factor b (P-TEFb) complex containing cyclin-
dependent kinase 9 and cyclin T1. The binding of the com-
plex facilitates transcription of the provirus by cellular RNA
polymerase II. In the absence of Tat, only short transcripts
are generated because RNA polymerase II is readily dissoci-
ated from the DNA template [15]. In this study, we found
in S. cerevisiae that Tat protein overexpression did not
Figure 5 Defects in gene expression of Gag VLPs containing a bicistronic expression cassette in target cells. (A) Schematical
representation of expression plasmids used for trans-packaging and subsequent protein expression. HIV-1 Gag expression plasmid and PGAP-
GagFL-IRES-EGFP-TGAP were used for production of Gag VLPs (as a helper plasmid) and synthesis of reporter RNA (as a vector plasmid),
respectively. HIV GagFL-EGFP was used as a control for GagFL and EGFP expression in mammalian cells. (B) Expression of HIV-1 GagFL and EGFP
in HeLa cells. Yeast was cotransformed with the helper and vector plasmids. After removal of the cell wall, yeast spheroplasts were cultured
overnight for Gag VLP release as before. Produced Gag VLPs (equivalent to 1 μg RNA) were added to HeLa cells. Following incubation at 37°C for
2 days, HeLa cells were subjected to immunostaining using anti-FLAG (for detection of GagFL) antibody. Nuclei were stained with DAPI.
Representative images were shown at the same magnification. Bar, 10 μm.
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the U3 region by the promoter for yeast GAP did support
the transcription (Figure 1), likely because the yeast pro-
moter is Tat-independent as opposed to the HIV-1 pro-
moter. It has also been suggested that cyclin T1 is a
species-specific cofactor for HIV-1 transcription, since
mouse cyclin T1 does not support HIV-1 transcription due
to a single amino acid change [52,53].
Translation of HIV-1 mRNA in yeast
The HIV-1 gag mRNA contains the R-U5 and SL regions
upstream from the gag start ATG codon. This 50 untrans-
lated region (332 bases) has been suggested to form a
highly folded RNA structure [29-31]. In cell-free systems
and Xenopus oocytes, the 50 untranslated region, especially
the TAR region, inhibits cap-dependent translation of the
gag gene [32-34,36]. A recent study showed that in 293 cells
the SL region, especially the Psi site, was the major deter-
minant of translation inhibition [35]. Consistent with these
studies, we found that in yeast, (i) the 50 untranslated region
had an inhibitory effect on the Gag translation without re-
ducing in the gag mRNA levels and (ii) no translation was
observed when the untranslated region included the TAR
region (Figure 2).
The 50 untranslated region is required for packaging of
HIV-1 genome into viral particles. Nevertheless, the 50 un-
translated region, if tested experimentally, inhibits its down-
stream Gag translation, which is required for virus particle
production. To explain this discrepancy, some hypotheses
have been proposed. One is the alternating structure model
of the 50 HIV-1 RNA, termed long-distance interaction
(LDI) and branched multiple hairpin (BMH): theequilibrium between the two was hypothesized to regulate
RNA dimerization, packaging, and translation [28,54,55].
However, mutations to alter the LDI-BMH equilibrium did
not affect translation efficiency [56]. Another possibility is
internal ribosome entry site (IRES) activity within the 50 un-
translated region of the HIV-1 RNA. An earlier study did
not identify putative IRES [36] and later studies found IRES
activity in a lentiviral family [57,58]. Interestingly, HIV-1
IRES functions only at the G2/M transition phase of the
cell cycle [57], although IRES-dependent Gag translation is
still controversial. In S. cerevisiae, IRES-mediated transla-
tion has been observed with endogenous yeast genes as well
as the IRES elements of hepatitis C virus [59], but neither
poliovirus nor encephalomyocarditis virus IRES can func-
tion [60,61]. In the present study, deletion of the entire 50
untranslated region (R-U5-SL) fully restored Gag transla-
tion. Thus, our study argues against the IRES-mediated
Gag translation although we cannot rule out a failure of the
IRES activity in yeast. It should be noted that in HIV-1
infected cells, the gag mRNA is efficiently translated to Gag
protein even though it contains the 50 untranslated region.
It is possible that a host factor(s), for examples, to unwind
the 50 RNA structures is involved in gag mRNA translation
in infec-ted cells. We suggest that complementation of host
factors, especially infection-induced host factors, to this
yeast cell system would identify such factors for gag
mRNA translation.
Genome packaging into Gag VLPs in yeast and the
benefits of yeast-derived Gag VLPs encapsidating genes
Results from numerous mutagenesis studies indicate that
each RNA element within the 50 untranslated region is
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mutations at the SL region (the DIS and Psi sites and the
gag start codon) severely impaired HIV-1 genome pack-
aging [38,39] and mutations at the TAR, pA, and PBS re-
gions similarly impaired the genome packaging [40,42],
indicating that the entire 50 untranslated region is involved
in efficient packaging of HIV-1 genome. These studies also
suggest that the structures, but not the specific sequences,
of the 50 untranslated region are important for packaging
of HIV-1 genome. In our study, the TAR-gag construct that
contained the full length of the R-U5-SL showed no Gag
protein expression. When the 50 untranslated region was
progressively truncated, the Gag protein was expressed but
the levels varied in the truncations. From these results, we
suppose that the cis-packaging efficiencies of these 50 trun-
cated RNAs are difficult to evaluate in a yeast cell system.
In contrast, our study indicated that HIV-1 genomic
RNA was preferentially incorporated into Gag VLPs in
yeast when Gag was supplied in trans. Generally, the tech-
nology of trans-packaging of gene is used to produce
replication-deficient viral vectors, which are much safer
than replication-competent viral vectors produced by cis-
packaging [44,45]. In the field of vaccinology, various types
of viral vaccines have been developed. Live attenuated vi-
ruses and recombinant viral vectors are the most effective
vaccines and stimulate cellular as well as humoral immune
responses. They replicate and express their antigens in
cells, but safety concerns cannot be excluded. In contrast,
viral protein components and peptides are safe but often
lack the ability to induce cellular immunity. VLPs are
highly assembled structures of viral protein components,
mimicking the authentic virion without including viral
genome. Thus, they are not infectious but often effective
at stimulating cellular immunity [62]. In fact, our previous
study showed that the Gag VLPs encased in yeast cell
membrane induced maturation and cross-presentation of
dendritic cells [21]. However, because VLPs do not contain
genetic materials, they do not endogenously produce
intracellular antigens that stimulates cellular immunity by
the major histocompatibility complex I antigen presenta-
tion pathway. Also, they usually do not contain viral enve-
lope glycoproteins that are major immunogens to elicit
neutralizing antibodies. Since yeast does not trim the gly-
cans to produce hyper-mannosylated glycans, it may not
be readily available for production of VLPs presenting gly-
coproteins on the VLP membrane at present [63]. Our
data suggest the possibility that noninfectious VLPs encap-
sidating gene of interest can be produced in a yeast cell
system and may provide clues to the development of yeast
VLP vaccines that confer ensured safety and enhanced im-
munogenicity. For this purpose, we produced Gag VLPs
packaging the bicistronic reporter gene cassettes (i.e., gagfl
and egfp) in a yeast cell system and tested expression of
the reporter genes transduced by Gag VLPs in HeLa andRaw264.7 cells. In this bicistronic construct, GagFL is
translated in a cap-dependent fashion, whereas EGFP is in
a cap-independent fashion. However, we did not see ex-
pression of GagFL or EGFP (Figure 5B, upper). We finally
isolated the RNA from the Gag VLPs and transfected the
RNA to HeLa cells but failed to see GagFL and EGFP ex-
pression (data not shown). These results suggested that
the failure of the transgene expression was not due to tar-
get cell types or the uncoating ability of Gag VLPs. Rather,
it is ascribable to extensive nicking of the RNA within Gag
VLPs. Retroviral/lentiviral gene expression requires re-
verse transcription of viral RNA and subsequent integra-
tion of the cDNA into host cell chromosomes before its
transcription and translation. The input viral RNA is not
directly used as mRNA and viral protein expression occurs
only from the integrated proviral cDNA. The reason is not
known but it may be partly that the RNA in viral particles
is randomly nicked [49,50]. However, we believe that
mRNA transduction without integration would be safer
and more suitable for vaccine design than stable integra-
tion of transgene into chromosomes. Further studies are
needed to develop the methods to incorporate intact
mRNA into Gag VLPs (e.g., by using non-cognate pack-
aging signals, by shortening transgene RNA, or by forming
stable RNA-protein complex like mature Gag capsid).
Conclusions
Cells of the yeast Saccharomyces cerevisiae have been used
to develop VLP vaccines (e.g., hepatitis B virus and human
papillomavirus). Such VLPs are considered new candidates
for safe and efficacious vaccine components because they
are noninfectious and highly immunogenic. Yeast cell sys-
tems have also been used as model cell systems with
which to study host factors required for the replication of
higher eukaryotic viruses. Bromo mosaic virus, a positive-
strand RNA virus, and human papillomavirus, a DNA
virus, have been shown to replicate and encapsidate their
genomes into virus particles in yeast. We previously dem-
onstrated the production of Gag VLPs in yeast sphero-
plasts. Our present study established the trans-packaging
of the HIV-1 genome into Gag VLPs in a yeast cell system.
This study also revealed that the 50 untranslated region of
the HIV-1 genome (the R-U5-SL region) inhibited its
downstream translation (Gag protein expression). This
yeast system may be useful for the study of HIV-1 genome
packaging and translation.
Methods
Plasmid construction and yeast expression
A full-length HIV-1 cDNA molecular clone, pNL43 [25],
was used for DNA construction. A Kpn I-Nhe I fragment
of the env gene (nucleotide positions 6343–7250) of
pNL43 was initially deleted (for biosafety), and the 30 LTR
was replaced by the terminator for the yeast GAP gene.
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mids containing the URA3 gene as a selective marker (re-
ferred to as HIV-TGAP). The U3 of the 5
0 LTR (HIV-1
promoter) was further replaced by the constitutive pro-
moter for the yeast GAP gene (referred to as PGAP-HIV-
TGAP). The entire 5
0 LTR and its downstream SL region,
including the gag start codon, were also deleted in the con-
text of PGAP-HIV-TGAP (referred to as PGAP-ΔHIV-TGAP).
A series of truncations of the 50 LTR and its downstream
SL regions was carried out by PCR using relevant forward
and reverse primers. For the expression of Gag protein in
trans, the full-length gag gene was placed under the control
of the GAP promoter, followed by the GAP terminator,
and the expression cassette was cloned into yeast 2 μ plas-
mid pRS423 containing the HIS3 gene as a selective
marker. For the expression of Tat and Rev proteins, the
exons of the tat and rev genes were joined by overlapping
PCR. The PCR fragments were similarly placed between
the GAP promoter and the GAP terminator and were
cloned into yeast 2 μ plasmid pRS423/424 containing the
HIS3/TRP1 gene as a selective marker. S. cerevisiae
strain RAY3A-D (MATa/α ura3/ura3 his3/his3 leu2/leu2
trp1/trp1) [64] was transformed by the recombinant
plasmids. The transformants were inoculated in the ap-
propriate synthetic medim and grown at 30°C.
For protein expression in mammalian cells, the bicis-
tronic IRES construct (the gag gene fused with a FLAG
epitope tag sequence, the IRES sequence derived from en-
cephalomyocarditis virus [Clontech], and the gene for egfp)
was initially generated in the pNL43 derivative with dele-
tions of the pol gene (nucleotide positions 2290–4553) and
the Kpn I-Nhe I fragment of the env gene (nucleotide posi-
tions 6343–7250). The 30 LTR and the U3 of the 50 LTR
were replaced by the terminator and the promoter for the
yeast GAP gene, respectively, and the resultant construct
was cloned into yeast 2 μ plasmid pKT10 [22] (referred to
as PGAP-GagFL-IRES-EGFP-TGAP). The pNL43 derivative
expressing the Gag protein fused with a FLAG epitope tag
and EGFP was similarly generated from the pNL43 deriva-
tive with deletions of the pol and env genes.
Preparation of yeast spheroplasts and production of
Gag VLPs
The procedure for yeast spheroplast formation was de-
scribed previously [20]. Yeast transformants were grown at
30°C in synthetic defined medium (0.67% yeast nitrogen
base, 2% glucose, and amino acid mixtures) without uracil,
histidine, and/or tryptophane. Yeast cells were suspended
in wash buffer (50 mM Tris [pH 7.5], 5 mM MgCl2, and 1
M sorbitol) containing 30 mM DTT and incubated at 30°C
for 20 min with gentle shaking. The cells were resuspended
in wash buffer containing 3 mM DTT and 0.4 mg/ml
Zymolyase and were incubated at 30°C for 20 min for cell
wall digestion. After being washed twice with 1 M sorbitol,spheroplasts were cultured in YPD (1% yeast extract, 2%
peptone, and 2% glucose) medium containing 1 M sorbitol
at 30°C overnight with gentle shaking (at 60 rpm).
Yeast-produced Gag VLPs were purified as described
previously [20]. Briefly, the culture medim of yeast sphero-
plasts was clarified and centrifuged through 30% (w/v) su-
crose cushions in an SW28 rotor (Beckman Coulter) at
120,000 × g for 1.5 hr at 4°C. The VLP pellets were re-
suspended in phosphate-buffered saline and were cen-
trifuged on 20-70% (w/v) sucrose gradients in an SW55
rotor (Beckman Coulter) at 120,000 × g overnight at 4°C.
Expression in mammalian cells
HeLa and Raw264.7 cells were grown in Eagle’s minimum
essential medium supplemented with 10% fetal bovine
serum. Gag VLPs (equivalent to 1 μg RNA) were added to
HeLa and Raw264.7 cells. Transfection with RNA isolated
from Gag VLPs or plasmid DNA was carried out using
Lipofectamine 2000 (Invitrogen).
Western blotting
Yeast cells (0.5 OD) were separated by SDS-PAGE.
Western blotting was carried out using anti-HIV-1 p24CA,
anti-HIV-1 Tat, and anti-HIV-1 Rev mouse monoclonal
antibodies (Advanced Biotechnologies).
Semi-quantitative and quantitative RT-PCRs
Total cellular RNA and VLP RNA were isolated with the
RNeasy kit (Qiagen) according to the manufacturer’s in-
structions. Contaminant DNA was digested with DNase I
during the isolation. Semi-quantitative RT-PCR was per-
formed with the ReverTra Dash kit (Toyobo) according to
the manufacturer’s instructions. For cDNA synthesis,
RNA was mixed with random primers and the reaction
was carried out at 42°C for 20 min. For amplification of
the cDNA, aliquots of the RT reaction samples were
mixed with 100 nM of each primer, and a three-step reac-
tion (98°C for 10 sec, 60°C for 2 sec, and 74°C for 30 sec)
was cycled. The following primer sets were used: 50-
ATGGGTGCGAGAGCGTCGGTATTAAGC-30 and 50-C




Real-time RT-PCR was performed with PrimeScript RT
reagent kit (Takara) and subsequently with SYBR Green
Realtime PCR Master Mix (Toyobo). For cDNA synthesis,
1 μg of RNA was mixed with a mixture of oligo dT and
random primers (supplied by the RT kit) and the reaction
was carried out at 37°C for 15 min according to the man-
ufacturer’s instruction. For amplification of the cDNA,
1/100th of aliquots of the reaction samples were mixed with
100 nM of each primer and two-step reaction (95°C for 5
sec and 60°C for 30 sec) was cycled. The following primer
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(confirmed by melting curve analysis): 50-GCTTGCTGA
AGCGCGCACGG-30 and 50-GACGCTCTCGCACCCAT
CTC-30 for unspliced HIV-1 (nucleotide positions 701–
806) [65] and 50-ATAATCCACCTATCCCAGTAGGAGA
AAT-30 and 50-TTTGGTCCTTGTCTTATGTCCAGAAT
GC-30 for HIV-1 gag (nucleotide positions 1544–1658) [66]
mRNAs. Relative quantification of HIV-1 RNA was
performed in reference to a standard curve prepared by
amplification of 10-fold serial dilutions (50–0.05 pg) of
pNL43 [25].
Northern blotting and slot blotting
Minus-strand RNA probes were synthesized with Maxi
script T7 kit (Ambion) according to the manufacturer0s in-
structions. The fragments of HIV-1 pol and yeast actin
genes (nucleotide positions 3826–4160 and 579–1436, re-
spectively) were cloned into pGEM3 vector (Promega) and
were in vitro-transcribed with biotinylated UTP (Roche) at
37°C for 60 min. After digestion of the DNA templates
with DNase I, RNA transcripts were purified using a Quick
Spin Column (Roche).
For Northern blotting, RNA samples were denatured,
electrophoresed in 0.8% agarose gels, and blotted onto
Hybond N+ membrane (Amersham). Hybridization and
detection were carried out with the Ultrahyb kit (Ambion)
and the Biotin Luminescent Detection kit (Roche) accor-
ding to the manufacturer’s instructions, respectively. Brie-
fly, hybridization with RNA probes was performed at 68°C
overnight and washing was performed first with 2×SSC
buffer containing 0.1% SDS and then with 0.1×SSC buffer
at 68°C. For slot-blot analysis, a series of dilutions of RNA
samples was blotted onto Hybond N+ membrane by vac-
uuming and hybridization and detection were similarly car-
ried out.
Immunofluorescent staining
Yeast cells were fixed in 3.7% formalin in YPD at 30°C for
30 min. Following removal of the cell wall, spheroplasts
were treated with 70% ethanol at 4°C for 5 min for mem-
brane permeabilization. After blocking with 0.1% BSA, cells
were incubated with anti-HIV-1 Tat or Rev mouse mono-
clonal antibodies and subsequently with anti-mouse IgG-
Alexa Fluor 488 (Molecular Probes). Nuclei were stained
with 40, 6-diamidino-2-phenylindole dihydrocloride (DAPI).
HeLa nad Raw264.7 cells were fixed in 3.7% formalin in
phosphate-buffered saline for 30 min and treated with 0.1%
Triton-X 100 for 10 min for membrane permeabilization.
After blocking with 0.1% BSA, cells were incubated with
anti-FLAG mouse monoclonal antibody (Sigma) and sub-
sequently with anti-mouse IgG-Alexa Fluor 568 (Molecu-
lar Probes). Nuclei were stained with DAPI. Cells were
observed with a laser-scanning confocal microscope
(TCS-SP5, Leica).Electron microscopy
Purified Gag VLP pellets were fixed in 2% glutaraldehyde
in 50 mM cacodylate buffer (pH 7.2) for 2 hr and
postfixed with 1% osmium tetroxide for 1 hr. The pellets
were embedded in epoxy resin. Ultrathin sections were
stained with uranyl acetate and lead citrate and were ex-
amined with an electron microscope.
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